# Mable

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mable-2

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.trymable.com
- Total disclosed funding: $3.2M
- Latest round: Seed (Jul 27, 2022)
- Investors on record: 5

## About

Founded in 2019 by Inna Nicole Thalmann, and Roman Rothaermel (CEO), and based in California, US, Neurolytic Healthcare, Inc., trading under the name Mable, operates as a health tech company that provides genomics-based telehealth services for migraine care. In July 2022, Neurolytic Healthcare, Inc. raised USD 3.2 million in seed funding led by investor Initialized Capital, with participation from an individual investor and Arkitekt Ventures and First In Capital.



The firm operates a platform that collects a combination of genetic and biomarker data to extract insights to offer enhanced diagnostics and provide personalized treatment for various neurological conditions. The platform offers online medical consultation services that include DNA testing services and offers precision and preventive treatment based on the DNA results for patients. 



The firm earns its revenue by offering its software and services at USD 279/month. 



The company intends to use the July 2022 financing for operation and business expansion.

## Funding rounds

- Seed, Jul 27, 2022, $3.2M — Illumina, Inc., Y Combinator, Initialized Capital, Arkitekt Ventures, First In Capital

## Investors

- Illumina, Inc. — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Initialized Capital (https://capitalatlas.ai/funds/initialized-capital) — Seed
- Arkitekt Ventures (https://capitalatlas.ai/funds/arkitekt-ventures) — Seed
- First In Capital (https://capitalatlas.ai/funds/first-in-capital) — Seed